Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Down 6.5%

Shares of Dianthus Therapeutics, Inc. (NASDAQ:DNTH) dropped 6.5% during trading on Wednesday . The company traded as low as $22.65 and last traded at $22.66. Approximately 39,372 shares were traded during mid-day trading, a decline of 75% from the average daily volume of 157,780 shares. The stock had previously closed at $24.24.

Analyst Ratings Changes

Several research analysts have recently weighed in on the stock. Raymond James boosted their price objective on shares of Dianthus Therapeutics from $34.00 to $51.00 and gave the stock an “outperform” rating in a research note on Thursday, April 18th. Wedbush boosted their price target on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a research report on Friday, May 10th. Jefferies Financial Group raised their price objective on Dianthus Therapeutics from $22.00 to $39.00 and gave the company a “buy” rating in a research report on Friday, March 22nd. HC Wainwright began coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They set a “buy” rating and a $40.00 target price on the stock. Finally, Lifesci Capital upgraded Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Six research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Dianthus Therapeutics has an average rating of “Buy” and an average price target of $42.83.

Dianthus Therapeutics Stock Performance

The company has a fifty day moving average of $23.68 and a two-hundred day moving average of $21.30.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, May 9th. The company reported ($0.54) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The firm had revenue of $0.87 million during the quarter, compared to the consensus estimate of $0.48 million. Analysts predict that Dianthus Therapeutics, Inc. will post -2.12 earnings per share for the current year.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Tower Research Capital LLC TRC acquired a new stake in Dianthus Therapeutics during the fourth quarter worth about $25,000. Citigroup Inc. acquired a new stake in shares of Dianthus Therapeutics during the 3rd quarter worth approximately $53,000. Acadian Asset Management LLC bought a new position in Dianthus Therapeutics in the third quarter valued at approximately $303,000. Virtu Financial LLC acquired a new position in Dianthus Therapeutics during the first quarter valued at approximately $390,000. Finally, Laurion Capital Management LP bought a new stake in Dianthus Therapeutics during the third quarter worth $497,000. 47.53% of the stock is currently owned by institutional investors and hedge funds.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.